KDR and acute myeloid leukemia: Vatalanib decreased VEGF levels and VEGFR phosphorylation in AML cells, which showed FLT3 internal tandem reduplications/mutations (ITD), raising the question of the actual targeted tyrosine kinase (VEGFR or flt3).